{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T06:14:12Z","timestamp":1769926452480,"version":"3.49.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1038\/ncpendmet0676","type":"journal-article","created":{"date-parts":[[2007,12,17]],"date-time":"2007-12-17T12:55:51Z","timestamp":1197896151000},"page":"44-52","source":"Crossref","is-referenced-by-count":23,"title":["Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist"],"prefix":"10.1038","volume":"4","author":[{"given":"Frances","family":"McManus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon T","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John MC","family":"Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BFncpendmet0676_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0960-0760(95)00021-Q","volume":"53","author":"JW Funder","year":"1995","unstructured":"Funder JW (1995) Mineralocorticoid receptors and hypertension. J Steroid Biochem Mol Biol 53: 53\u201355","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BFncpendmet0676_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.mce.2003.10.018","volume":"217","author":"R Losel","year":"2004","unstructured":"Losel R  et al. (2004) A quick glance at rapid aldosterone action. Mol Cell Endocrinol 217: 137\u2013141","journal-title":"Mol Cell Endocrinol"},{"key":"BFncpendmet0676_CR3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3317\/jraas.2002.043","volume":"3","author":"SM MacKenzie","year":"2002","unstructured":"MacKenzie SM  et al. (2002) Local renin\u2013angiotensin systems and their interactions with extra-adrenal corticosteroid production. J Renin Angiotensin Aldosterone Syst 3: 214\u2013221","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"BFncpendmet0676_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1677\/joe.1.06017","volume":"186","author":"JM Connell","year":"2002","unstructured":"Connell JM and Davies E (2002) The new biology of aldosterone. J Endocrinol 186: 1\u201320","journal-title":"J Endocrinol"},{"key":"BFncpendmet0676_CR5","doi-asserted-by":"publisher","first-page":"E386","DOI":"10.1152\/ajpendo.2000.279.2.E386","volume":"279","author":"P Penfornis","year":"2000","unstructured":"Penfornis P  et al. (2000) The mineralocorticoid receptor mediates aldosterone-induced differentiation of T37i cells into brown adipocytes. Am J Physiol Endocrinol Metab 279: E386\u2013E394","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"BFncpendmet0676_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/00041552-200403000-00007","volume":"13","author":"EP Gomez-Sanchez","year":"2004","unstructured":"Gomez-Sanchez EP (2004) Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. Curr Opin Nephrol Hypertens 13: 191\u2013196","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"BFncpendmet0676_CR7","doi-asserted-by":"publisher","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","volume":"283","author":"R Rocha","year":"2002","unstructured":"Rocha R (2002) Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283: H1802\u2013H1810","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"BFncpendmet0676_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3317\/jraas.2003.025","volume":"4","author":"B Pitt","year":"2003","unstructured":"Pitt B  et al. (2003) Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. J Renin Angiotensin Aldosterone Syst 4: 164\u2013168","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"BFncpendmet0676_CR9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1210\/en.2002-220926","volume":"144","author":"MJ Young","year":"2003","unstructured":"Young MJ  et al. (2003) Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 \u03b2-hydroxysteroid dehydrogenase inactivation. Endocrinology 144: 1121\u20131125","journal-title":"Endocrinology"},{"key":"BFncpendmet0676_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jsbmb.2004.12.010","volume":"93","author":"JW Funder","year":"2005","unstructured":"Funder JW (2005) RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 93: 121\u2013125","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BFncpendmet0676_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(05)74868-6","volume":"353","author":"PO Lim","year":"1999","unstructured":"Lim PO  et al. (1999) Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 353: 40","journal-title":"Lancet"},{"key":"BFncpendmet0676_CR12","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","volume":"40","author":"DA Calhoun","year":"2002","unstructured":"Calhoun DA  et al. (2002) Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40: 892\u2013896","journal-title":"Hypertension"},{"key":"BFncpendmet0676_CR13","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"Rossi GP  et al. (2006) A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48: 2293\u20132300","journal-title":"J Am Coll Cardiol"},{"key":"BFncpendmet0676_CR14","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","volume":"27","author":"GP Rossi","year":"1996","unstructured":"Rossi GP  et al. (1996) Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 27: 1039\u20131045","journal-title":"Hypertension"},{"key":"BFncpendmet0676_CR15","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P  et al. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45: 1243\u20131248","journal-title":"J Am Coll Cardiol"},{"key":"BFncpendmet0676_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa033263","volume":"351","author":"RS Vasan","year":"2004","unstructured":"Vasan RS  et al. (2004) Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 351: 33\u201341","journal-title":"N Engl J Med"},{"key":"BFncpendmet0676_CR17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1161\/01.HYP.0000258554.87444.91","volume":"49","author":"C Newton-Cheh","year":"2007","unstructured":"Newton-Cheh C  et al. (2007) Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension 49: 846\u2013856","journal-title":"Hypertension"},{"key":"BFncpendmet0676_CR18","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","volume":"114","author":"F Beygui","year":"2006","unstructured":"Beygui F  et al. (2006) High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 114: 2604\u20132610","journal-title":"Circulation"},{"key":"BFncpendmet0676_CR19","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1053\/euhj.1998.1093","volume":"19","author":"P Vantrimpont","year":"1998","unstructured":"Vantrimpont P  et al. (1998) Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 19: 1552\u20131563","journal-title":"Eur Heart J"},{"key":"BFncpendmet0676_CR20","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","volume":"82","author":"K Swedberg","year":"1990","unstructured":"Swedberg K  et al. (1990) Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82: 1730\u20131736","journal-title":"Circulation"},{"key":"BFncpendmet0676_CR21","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","volume":"115","author":"G Guder","year":"2007","unstructured":"Guder G  et al. (2007) Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115: 1754\u20131761","journal-title":"Circulation"},{"key":"BFncpendmet0676_CR22","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","volume":"67","author":"CG Brilla","year":"1990","unstructured":"Brilla CG  et al. (1990) Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67: 1355\u20131364","journal-title":"Circ Res"},{"key":"BFncpendmet0676_CR23","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","volume":"31","author":"R Rocha","year":"1998","unstructured":"Rocha R  et al. (1998) Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31: 451\u2013458","journal-title":"Hypertension"},{"key":"BFncpendmet0676_CR24","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha R  et al. (2000) Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141: 3871\u20133878","journal-title":"Endocrinology"},{"key":"BFncpendmet0676_CR25","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi ER  et al. (2003) Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63: 1791\u20131800","journal-title":"Kidney Int"},{"key":"BFncpendmet0676_CR26","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"McKelvie RS  et al. (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100: 1056\u20131064","journal-title":"Circulation"},{"key":"BFncpendmet0676_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S1388-9842(99)00046-X","volume":"1","author":"AF Lee","year":"1999","unstructured":"Lee AF  et al. (1999) Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1: 401\u2013406","journal-title":"Eur J Heart Fail"},{"key":"BFncpendmet0676_CR28","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B  et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709\u2013717","journal-title":"N Engl J Med"},{"key":"BFncpendmet0676_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2003.10.004","volume":"217","author":"SAS Tait","year":"2004","unstructured":"Tait SAS  et al. (2004) The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function. Mol Cell Endocrinol 217: 1\u201321","journal-title":"Mol Cell Endocrinol"},{"key":"BFncpendmet0676_CR30","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","volume":"60","author":"X Jeunemaitre","year":"1987","unstructured":"Jeunemaitre X  et al. (1987) Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 60: 820\u2013825","journal-title":"Am J Cardiol"},{"key":"BFncpendmet0676_CR31","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N  et al. (2007) Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49: 839\u2013845","journal-title":"Hypertension"},{"key":"BFncpendmet0676_CR32","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK  et al. (2003) Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16: 925\u2013930","journal-title":"Am J Hypertens"},{"key":"BFncpendmet0676_CR33","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","volume":"25","author":"DA Lane","year":"2007","unstructured":"Lane DA  et al. (2007) Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 25: 891\u2013894","journal-title":"J Hypertens"},{"key":"BFncpendmet0676_CR34","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1365-2125.1982.tb01383.x","volume":"13","author":"GT McInnes","year":"1982","unstructured":"McInnes GT  et al. (1982) Relative potency and structure activity relationships of aldosterone antagonists in healthy man: correlation with animal experience. Br J Clin Pharmacol 13: 331\u2013339","journal-title":"Br J Clin Pharmacol"},{"key":"BFncpendmet0676_CR35","first-page":"650","volume":"240","author":"M De Gasparo","year":"1987","unstructured":"De Gasparo M  et al. (1987) Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro . J Pharmacol Exp Ther 240: 650\u2013656","journal-title":"J Pharmacol Exp Ther"},{"key":"BFncpendmet0676_CR36","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0022-4731(89)90169-6","volume":"32","author":"M De Gasparo","year":"1989","unstructured":"De Gasparo M  et al. (1989) Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 32: 223\u2013227","journal-title":"J Steroid Biochem"},{"key":"BFncpendmet0676_CR37","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1161\/01.CIR.0000039328.33137.6C","volume":"106","author":"P Lacolley","year":"2002","unstructured":"Lacolley P  et al. (2002) Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation 106: 2848\u20132853","journal-title":"Circulation"},{"key":"BFncpendmet0676_CR38","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","volume":"105","author":"S Rajagopalan","year":"2002","unstructured":"Rajagopalan S  et al. (2002) Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105: 2212\u20132216","journal-title":"Circulation"},{"key":"BFncpendmet0676_CR39","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1161\/01.ATV.0000204635.75748.0f","volume":"26","author":"J Suzuki","year":"2006","unstructured":"Suzuki J  et al. (2006) Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 26: 917\u2013921","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFncpendmet0676_CR40","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/01.HYP.0000184640.81730.22","volume":"46","author":"S Takai","year":"2005","unstructured":"Takai S  et al. (2005) Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 46: 1135\u20131139","journal-title":"Hypertension"},{"key":"BFncpendmet0676_CR41","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1161\/01.HYP.0000128031.31572.a3","volume":"43","author":"DH Endemann","year":"2004","unstructured":"Endemann DH  et al. (2004) Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 43: 1252\u20131257","journal-title":"Hypertension"},{"key":"BFncpendmet0676_CR42","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","volume":"33","author":"R Rocha","year":"1999","unstructured":"Rocha R  et al. (1999) Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232\u2013237","journal-title":"Hypertension"},{"key":"BFncpendmet0676_CR43","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000077396","volume":"24","author":"X Zhou","year":"2004","unstructured":"Zhou X  et al. (2004) Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME\/SHR model. Am J Nephrol 24: 242\u2013249","journal-title":"Am J Nephrol"},{"key":"BFncpendmet0676_CR44","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1210\/en.2006-0944","volume":"147","author":"C Guo","year":"2006","unstructured":"Guo C  et al. (2006) Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 147: 5363\u20135373","journal-title":"Endocrinology"},{"key":"BFncpendmet0676_CR45","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","volume":"25","author":"ED Burgess","year":"2003","unstructured":"Burgess ED  et al. (2003) Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 25: 2388\u20132404","journal-title":"Clin Ther"},{"key":"BFncpendmet0676_CR46","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH  et al. (2002) Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15: 709\u2013716","journal-title":"Am J Hypertens"},{"key":"BFncpendmet0676_CR47","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN  et al. (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543\u2013551","journal-title":"N Engl J Med"},{"key":"BFncpendmet0676_CR48","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","volume":"41","author":"WB White","year":"2003","unstructured":"White WB  et al. (2003) Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41: 1021\u20131026","journal-title":"Hypertension"},{"key":"BFncpendmet0676_CR49","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","volume":"93","author":"GH Williams","year":"2004","unstructured":"Williams GH  et al. (2004) Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 93: 990\u2013996","journal-title":"Am J Cardiol"},{"key":"BFncpendmet0676_CR50","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","volume":"150","author":"MH Weinberger","year":"2005","unstructured":"Weinberger MH  et al. (2005) Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 150: 426\u2013433","journal-title":"Am Heart J"},{"key":"BFncpendmet0676_CR51","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","volume":"41","author":"JM Flack","year":"2003","unstructured":"Flack JM  et al. (2003) Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 41: 1148\u20131155","journal-title":"J Am Coll Cardiol"},{"key":"BFncpendmet0676_CR52","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1177\/0091270003258189","volume":"43","author":"LM Prisant","year":"2003","unstructured":"Prisant LM  et al. (2003) Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? J Clin Pharmacol 43: 1203\u20131210","journal-title":"J Clin Pharmacol"},{"key":"BFncpendmet0676_CR53","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum H  et al. (2002) Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40: 117\u2013123","journal-title":"Hypertension"},{"key":"BFncpendmet0676_CR54","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B  et al. (2003) Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108: 1831\u20131838","journal-title":"Circulation"},{"key":"BFncpendmet0676_CR55","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A  et al. (2003) Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41: 64\u201368","journal-title":"Hypertension"},{"key":"BFncpendmet0676_CR56","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.00240106","volume":"1","author":"M Epstein","year":"2006","unstructured":"Epstein M  et al. (2006) Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1: 940\u2013951","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFncpendmet0676_CR57","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B  et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309\u20131321","journal-title":"N Engl J Med"},{"key":"BFncpendmet0676_CR58","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1161\/01.CIR.0000039104.56479.42","volume":"106","author":"G Suzuki","year":"2002","unstructured":"Suzuki G  et al. (2002) Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106: 2967\u20132972","journal-title":"Circulation"},{"key":"BFncpendmet0676_CR59","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad F  et al. (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). RALES Investigators. Circulation 102: 2700\u20132706","journal-title":"Circulation"},{"key":"BFncpendmet0676_CR60","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/j.1540-8167.2006.00372.x","volume":"17","author":"SC Shroff","year":"2006","unstructured":"Shroff SC  et al. (2006) Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol 17: 534\u2013541","journal-title":"J Cardiovasc Electrophysiol"},{"key":"BFncpendmet0676_CR61","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3317\/jraas.2006.005","volume":"7","author":"WC De Mello","year":"2006","unstructured":"De Mello WC (2006) Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart. J Renin Angiotensin Aldosterone Syst 7: 40\u201346","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"BFncpendmet0676_CR62","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/heart.88.5.475","volume":"88","author":"CA Farquharson","year":"2002","unstructured":"Farquharson CA and Struthers AD (2002) Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure. Heart 88: 475\u2013480","journal-title":"Heart"},{"key":"BFncpendmet0676_CR63","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1210\/jc.2007-0393","volume":"92","author":"HV Joffe","year":"2007","unstructured":"Joffe HV  et al. (2007) Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab 92: 2552\u20132558","journal-title":"J Clin Endocrinol Metab"},{"key":"BFncpendmet0676_CR64","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/eurheartj\/ehi204","volume":"26","author":"K Swedberg","year":"2005","unstructured":"Swedberg K  et al. (2005) Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26: 1115\u20131140","journal-title":"Eur Heart J"},{"key":"BFncpendmet0676_CR65","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ejheart.2007.04.004","volume":"9","author":"JG Cleland","year":"2007","unstructured":"Cleland JG  et al. (2007) Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet. Eur J Heart Fail 9: 740\u2013745","journal-title":"Eur J Heart Fail"}],"container-title":["Nature Clinical Practice Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0676","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0676.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpendmet0676.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T19:54:36Z","timestamp":1684439676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpendmet0676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["BFncpendmet0676"],"URL":"https:\/\/doi.org\/10.1038\/ncpendmet0676","relation":{},"ISSN":["1745-8366","1745-8374"],"issn-type":[{"value":"1745-8366","type":"print"},{"value":"1745-8374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]}}}